ES2547248T3 - Anticuerpos que se unen al dominio extracelular del receptor Tirosina cinasa ALK - Google Patents

Anticuerpos que se unen al dominio extracelular del receptor Tirosina cinasa ALK Download PDF

Info

Publication number
ES2547248T3
ES2547248T3 ES07720099.6T ES07720099T ES2547248T3 ES 2547248 T3 ES2547248 T3 ES 2547248T3 ES 07720099 T ES07720099 T ES 07720099T ES 2547248 T3 ES2547248 T3 ES 2547248T3
Authority
ES
Spain
Prior art keywords
seq
antibody
alk
scfv antibody
scfv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07720099.6T
Other languages
English (en)
Spanish (es)
Inventor
Adrian Auf Der Maur
Peter Lichtlen
Alcide Barberis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delenex Therapeutics AG
Original Assignee
Delenex Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delenex Therapeutics AG filed Critical Delenex Therapeutics AG
Application granted granted Critical
Publication of ES2547248T3 publication Critical patent/ES2547248T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES07720099.6T 2006-04-28 2007-04-27 Anticuerpos que se unen al dominio extracelular del receptor Tirosina cinasa ALK Active ES2547248T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79583106P 2006-04-28 2006-04-28
US795831P 2006-04-28
PCT/CH2007/000202 WO2007124610A1 (en) 2006-04-28 2007-04-27 Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk

Publications (1)

Publication Number Publication Date
ES2547248T3 true ES2547248T3 (es) 2015-10-02

Family

ID=38515389

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07720099.6T Active ES2547248T3 (es) 2006-04-28 2007-04-27 Anticuerpos que se unen al dominio extracelular del receptor Tirosina cinasa ALK

Country Status (16)

Country Link
US (3) US7902340B2 (https=)
EP (2) EP2013236B1 (https=)
JP (2) JP5431920B2 (https=)
KR (1) KR101457228B1 (https=)
CN (1) CN101443361B (https=)
AU (1) AU2007246144B2 (https=)
BR (1) BRPI0710971A2 (https=)
CA (1) CA2650822C (https=)
DK (1) DK2013236T3 (https=)
ES (1) ES2547248T3 (https=)
IL (1) IL194752A0 (https=)
MX (1) MX2008013705A (https=)
NZ (1) NZ572248A (https=)
PL (1) PL2013236T3 (https=)
RU (1) RU2460540C2 (https=)
WO (1) WO2007124610A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710971A2 (pt) * 2006-04-28 2011-05-31 Esbatech Ag anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
PL2307458T3 (pl) * 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
HK1220465A1 (zh) 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
CN104861069B (zh) * 2014-02-21 2018-12-18 无锡傲锐东源生物科技有限公司 针对间变性淋巴瘤激酶的单克隆抗体1a4及其用途
WO2015184231A2 (en) * 2014-05-30 2015-12-03 Kolltan Pharmaceuticals, Inc. Regulators of anaplastic lymphoma kinase and uses thereof
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
CA2940470C (en) 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
MY196631A (en) 2015-10-13 2023-04-24 Eureka Therapeutics Inc Antibody Agents Specific for Human Cd19 and uses Thereof
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
WO2017147408A1 (en) * 2016-02-25 2017-08-31 The Regents Of The University Of California Methods for the treatment of hematologic cancer
JP7538601B2 (ja) 2017-04-26 2024-08-22 ユーリカ セラピューティックス， インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
JP7654402B2 (ja) * 2018-02-09 2025-04-01 アクセルロン ファーマ インコーポレイテッド 異所性骨化を処置するための方法
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN113960313B (zh) * 2021-12-22 2022-04-12 上海思路迪医学检验所有限公司 一种外泌体alk融合蛋白磁免疫化学发光检测试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21505A (en) * 1858-09-14 Improvement in bullet-machines
US6696548B2 (en) * 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
WO1998002462A1 (en) 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
JPH1116250A (ja) * 1997-06-20 1999-01-22 Pioneer Electron Corp 情報再生システム
ATE273323T1 (de) * 1999-12-28 2004-08-15 Esbatech Ag INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
CA2412650C (en) 2000-06-14 2011-08-02 Georgetown University Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
JP2006508638A (ja) * 2002-05-22 2006-03-16 エスバテック・アーゲー 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
US7888485B2 (en) 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
WO2006020684A2 (en) 2004-08-10 2006-02-23 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
BRPI0710971A2 (pt) * 2006-04-28 2011-05-31 Esbatech Ag anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk

Also Published As

Publication number Publication date
RU2008146922A (ru) 2010-06-10
NZ572248A (en) 2011-08-26
RU2460540C2 (ru) 2012-09-10
JP5431920B2 (ja) 2014-03-05
JP2013226144A (ja) 2013-11-07
JP5911821B2 (ja) 2016-04-27
CA2650822C (en) 2017-03-14
AU2007246144B2 (en) 2012-12-06
CN101443361B (zh) 2015-08-19
JP2009535021A (ja) 2009-10-01
US20110159008A1 (en) 2011-06-30
EP2013236A1 (en) 2009-01-14
BRPI0710971A2 (pt) 2011-05-31
US9512411B2 (en) 2016-12-06
HK1124619A1 (en) 2009-07-17
IL194752A0 (en) 2011-08-01
AU2007246144A1 (en) 2007-11-08
CN101443361A (zh) 2009-05-27
DK2013236T3 (en) 2015-09-21
US20080118512A1 (en) 2008-05-22
MX2008013705A (es) 2008-11-06
CA2650822A1 (en) 2007-11-08
EP2013236B1 (en) 2015-06-17
EP2604627A1 (en) 2013-06-19
KR101457228B1 (ko) 2014-11-04
KR20080113261A (ko) 2008-12-29
US7902340B2 (en) 2011-03-08
US8945563B2 (en) 2015-02-03
PL2013236T3 (pl) 2015-12-31
US20150203829A1 (en) 2015-07-23
WO2007124610A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
ES2547248T3 (es) Anticuerpos que se unen al dominio extracelular del receptor Tirosina cinasa ALK
ES2317020T3 (es) Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i y la utilizacion de los mismos.
KR102125032B1 (ko) 인간 dlk1에 대한 항체 및 이의 용도
CN109862913B (zh) 用于免疫疗法的αvβ8整联蛋白复合物的中和抗体
CA2248233A1 (en) Delivery system using mab 3e10 and mutants and/or functional fragments thereof
US12195540B2 (en) Antibodies that bind integrin αvβ8 and uses thereof
WO2012162418A1 (en) Methods and compositions for heterodimeric targeting ligands
JP2019146571A (ja) 抗インテグリンβ１抗体組成物及びその使用方法
KR20190143826A (ko) 세포/조직 특이적 세포 침투 항체
Kuan et al. Affinity‐matured anti‐glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas
CN112105643A (zh) 治疗性抗体及其应用
TW201736399A (zh) 抗vegfr抗體及其應用
WO2025026358A1 (zh) Muc1结合分子和包含其的嵌合抗原受体
Wei et al. CF750‐A33scFv‐Fc‐Based Optical Imaging of Subcutaneous and Orthotopic Xenografts of GPA33‐Positive Colorectal Cancer in Mice
AU2012244351B2 (en) Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK
TWI904701B (zh) 抗ceacam5/6雙結合抗體
Cabanillas-Bernal et al. variable single domains (VNARs): broadly neutralizing tools for
WO2022267926A1 (zh) 一种抗tnfr2抗体及其制备方法和应用
HK40105152A (zh) 对muc18特异性的抗体
HK1124619B (en) Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
HK40060753B (zh) 对muc18特异性的抗体
HK40008779B (zh) 用於免疫疗法的αvβ8整联蛋白复合物的中和抗体
TW201904992A (zh) 抗人類血管內皮生長因子受體之抗體及其應用